Biotech Values

[rfj1862]

RPRX

Think Equity went from a $31 May price target to $18 and dropped Androxal from the future valuation model. I think I know why. It had heretofor been the larger part of the future revenue model. Do you have access to their report in making that move?

No, I do not have access to that report. However, it came out after the R&R conference; suggests they thought twice about the soft end points for Androxal.

What penetration level and % does their royalty revenue from Proellex presume?
Royalty value is not the issue here. Sale of the program and/or the company is.

Does Think Equity seem to be aware that the Schering Plough P3 trial for Asoprisnil is not on Schering's planning horizon due to long term effects that showed up only in longer term trials?
One would hope, although the endometrial thickening issue showed up at 3 mo. Not sure where you're getting the LT crap.

Do you know when the adverse side effects of RU 486 became apparent in their fibroid testing?
In the most recent trial of RU486, there was no thickening after 6 mo.